Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6859 pages
Showing 6351 - 6400Deviation From NCCN Guidelines May Result in Greater Costs for Patients With Metastatic Breast Cancer
A study published by Williams et al in JNCCN—Journal of the National Comprehensive Cancer Network found that direct costs for patients with metastatic breast cancer increased when their treatment differed from recommendations found in the NCCN Clinical Practice Guidelines in Oncology® (NCCN...
High Blood Pressure and Cardiac Adverse Events in Patients Treated With Ibrutinib
Over half of patients treated with the Bruton’s tyrosine kinase inhibitor ibrutinib developed new or worsened high blood pressure within 6 months of starting the medication, according to a study published by Dickerson et al in Blood. The analysis is also the first to tie ibrutinib-related...
ASCO Breakthrough: Breast Cancer Gene-Expression Signature May Help Predict Recurrence Postradiotherapy
Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of...
ASCO Breakthrough: Effect of ATM Mutations on Response to Radiotherapy
Somatic mutations of DNA damage repair genes like ATM and BRCA1 or BRCA2 may result in poor disease prognosis and chemotherapy resistance. However, a study by Lee et al presented at ASCO Breakthrough: A Global Summit for Oncology Innovators (Abstract 130) investigated the possibility that these...
Andrew C. von Eschenbach, MD, Honored for Leadership in National Lung Screening Trial
The Prevent Cancer Foundation recently honored Andrew C. von Eschenbach, MD, with the James L. Mulshine, MD, Leadership Award for his work leading the National Lung Screening Trial (NLST), the first large-scale clinical trial for low-dose computed tomography (CT) lung cancer screening. The award...
Susan G. Komen Unveils $26 Million Investment in Research and Treatments in Metastatic Breast Cancer
SUSAN G. KOMEN recently announced $26 million in funding for new research projects that focus on metastatic breast cancer, new treatments, and disparities in breast cancer outcomes. This year’s grant slate focuses on key areas that will help the organization achieve its bold goal to reduce the...
Survey Identifies Gap in Culturally Competent Cancer Care for LGBTQI+ Latinx Population
Most Latinx people who are LGBTQI+ (lesbian, gay, bisexual, transgender, queer, and intersex) reported being reluctant to share their gender identity and/or sexual orientation with a health-care provider, and a majority have never received cancer information tailored for their community, according...
Vassiliki Papadimitrakopoulou, MD, Appointed Clinical Development Leader of Pfizer Oncology
Vassiliki Papadimitrakopoulou, MD, has been appointed Clinical Development Leader of Pfizer Oncology. Dr. Papadimitrakopoulou will be based in New York City. Recognized around the world for her expertise in personalized genomics-driven cancer therapies, immunotherapies, translational research, and ...
Horwitz Prize Awarded to Three Scientists for Work on Critical Cancer Pathway
Columbia University awarded the 2019 Louisa Gross Horwitz Prize to three scientists: Lewis C. Cantley, PhD, of Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, New York; David M. Sabatini, MD, PhD, of Massachusetts Institute of Technology, Cambridge, Massachusetts, and ...
Higher-Volume Cancer Centers and Patient Outcomes Studies
RESEARCHERS FROM Fox Chase Cancer Center have discovered a link between higher patient volume at cancer facilities and improved survival in two studies of patients with advanced cancer.1,2 These data underscore the ability of a higher-volume facility to provide patients with more experience and...
City of Hope Researchers Receive Awards and Grants
City of Hope recently announced that several of its researchers and faculty have been named as the recipients of several awards and grants. These accolades recognize individuals for their work in their respective fields of human genetics education, genomic research, and leptomeningeal disease....
Study Shows Benefits of Comprehensive Tobacco Treatment Program
Findings from a large smoking cessation study in patients with cancer indicate comprehensive tobacco treatment is effective in helping individuals successfully quit and abstain from smoking. The prospective study, published by Paul Cinciripini, PhD, Chair of Behavioral Science at the MD Anderson...
Kidney Cancer Association Announces Recipients of Advanced Discovery and Young Investigator Awards
The Kidney Cancer Association has announced the recipients of the Advanced Discovery Awards (ADAs) and Young Investigator Awards (YIAs). In April, the Kidney Cancer Association approved $1.3 million in new grant funding to advance early detection and new treatments of kidney cancer. Established...
Resistance to Immune Checkpoint Blocker May Be Linked to Metabolic Imbalance
A metabolic imbalance in some patients with cancer, following treatment with the checkpoint inhibitor nivolumab, may be associated with resistance to immunotherapy and shorter survival, according to scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of...
Lisa M. DeAngelis, MD, Named Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering
The Memorial Sloan Kettering (MSK) Cancer Center recently announced that Lisa M. DeAngelis, MD, has been named Physician-in-Chief and Chief Medical Officer. An expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was Co-Founder of MSK’s Brain Tumor...
Cleveland Clinic Appoints Jame Abraham, MD, FACP, as Department Chair of Hematology/Medical Oncology
Jame Abraham, MD, FACP, has been appointed the new Chair of the Hematology/Medical Oncology Department at Cleveland Clinic. In this capacity, he will recruit and develop staff as well as guide the department’s focus on patient access and a multidisciplinary approach to care. Dr. Abraham currently...
Recent Trends in the Treatment and Prognosis of Male Breast Cancer
A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival. Male breast cancer comprises 1% of all...
Impact of Treating Facility, Provider Volume, and Patient-Sharing in the Treatment of Patients With Multiple Myeloma
A study published by Freeman et al in JNCCN—Journal of the National Comprehensive Cancer Network found that generally, providers with more experience treating multiple myeloma have better outcomes than those with more limited experience. Providers who saw the most cases were more likely to be...
Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses results from a long-term follow-up of a cohort treated with docetaxel in the STAMPEDE randomized trial, confirming that the treatment showed benefit in patients with both high- and low-volume disease (Abstract...
Nicholas D. James, PhD, MBBS, on Prostate Cancer: STAMPEDE Trial M1|RT Comparison of Radiotherapy
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without docetaxel in patients with prostate cancer with only lymph node metastases or less than four bone metastases (Abstract 844O).
Jorge J. Castillo, MD, on Evolution of Therapy for Relapsed/Refractory Multiple Myeloma
Jorge J. Castillo, MD, of Dana-Farber Cancer Institute, discusses the many advances in treating relapsed and/or refractory multiple myeloma, including novel immunomodulators, proteasome inhibitors, and monoclonal antibodies, as well as emerging treatments such as chimeric antigen receptor T-cell...
Rafael Bejar, MD, PhD, on Myelodysplastic Syndromes: Advances in Personalized Therapeutic Approaches
Rafael Bejar, MD, PhD, of the University of California, San Diego Moores Cancer Center, discusses the tailored nature of MDS treatment, including somatic mutations that could alter treatment decisions, and novel therapies with predictive biomarkers.
Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?
Nina Shah, MD, of the University of California, San Francisco, discusses the debate on fixed duration vs waiting until disease progression, a key question for clinicians treating patients with multiple myeloma.
Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy
Richard I. Fisher, MD, of Fox Chase Cancer Center, discusses the improvement in survival for patients with follicular lymphoma, new targeted biologic agents providing alternative treatments, and chemoimmunotherapy (a standard in many cases).
Nitin Jain, MD, on CLL: Is There a Role for Chemoimmunotherapy?
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses the debate on evolving strategies in first-line treatment of CLL.
William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, offers commentary on the debate about evolving strategies in first-line chronic lymphocytic leukemia, the clinical trials on such agents as ibrutinib, BTK inhibitors, and venetoclax, and the interest in...
Andrew D. Zelenetz, MD, PhD, on The Era of Therapeutic Biosimilars: What You Need to Know
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the nature of biologic molecules and their importance in future therapeutic innovation.
Preclinical Study Finds Exposure to E-Cigarette Smoke Increased Risk of Cancer in Mice
Exposure to e-cigarette smoke caused mice to develop lung cancer, according to findings from a preclinical study published by Tang et al in the Proceedings of National Academy of Sciences of the United States of America (PNAS). The study found that 9 of 40 mice (22.5%) exposed to e-cigarette smoke...
2019 Nobel Prize in Physiology or Medicine Announced
Today, the Nobel Assembly at Karolinska Institutet announced its decision to award the 2019 Nobel Prize in Physiology or Medicine jointly to William G. Kaelin Jr, MD; Sir Peter J. Ratcliffe, FRS; and Gregg L. Semenza, MD, PhD, for their discoveries of how cells sense and adapt to oxygen...
ESMO 2019: Liquid Biopsy to Determine Best Treatment for Patients With NSCLC
Patients with advanced lung cancer might soon be offered a blood test that could help decide the best treatment for them, instead of relying on tumor biopsy analysis. New data from the BFAST trial presented by Gadgeel et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract ...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer
Induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) followed by surgical exploration induced high conversion rates in patients with locally advanced pancreatic cancer, and conversion was associated with...
ESMO 2019: 3-Year Results From CheckMate 238: Adjuvant Nivolumab vs Ipilimumab in Advanced Melanoma
Superior recurrence-free survival benefit was observed with nivolumab vs ipilimumab—and was consistent across disease stage, programmed cell death ligand 1 (PD-L1) expression levels, and BRAF mutation status—in patients with resected stage III/IV melanoma and a high risk of recurrence, according to ...
ESMO 2019: Personalized Treatment for Head and Neck Cancer Based on Geriatric Assessment
Fit elderly patients aged 70 years and older with head and neck squamous cell carcinoma were able to undergo rigorous treatment that provided benefit similar to that observed in younger patients. However, elderly patients with head and neck squamous cell carcinoma classified by geriatric assessment ...
ESMO 2019: Lenvatinib for Advanced Thymic Carcinoma
Patients with thymic carcinoma that has progressed following treatment with platinum-based chemotherapy may benefit from treatment with lenvatinib, according to findings from a phase II study reported by Itoh et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract ...
ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma
Patients with locally advanced or metastatic urothelial carcinoma demonstrated prolonged progression-free survival with the addition of atezolizumab to first-line platinum-based chemotherapy vs treatment with chemotherapy alone, according to phase III data from the IMvigor130 study presented by...
ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma
Patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation showed clinical benefit and improved progression-free survival (PFS) when treated with ivosidenib vs placebo, according to results presented by Ghassan K. Abou-Alfa, MD, at the European Society for Medical...
ESMO 2019: BROCADE 3: Veliparib Plus Carboplatin/Paclitaxel in Patients With HER2-Negative, Germline BRCA-Mutated Advanced Breast Cancer
Patients with advanced or metastatic HER2-negative breast cancer with a germline BRCA mutation demonstrated significantly improved progression-free survival (PFS) with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to chemotherapy (comprised of carboplatin/paclitaxel)...
ESMO 2019: LIBRETTO-001 Trial of Selpercatinib in RET Fusion–Positive Thyroid Cancer
Patients with advanced RET fusion–positive thyroid cancer and RET-mutant medullary thyroid cancer had high rates of response following treatment with selpercatinib, according to findings from the phase I/II LIBRETTO-001 trial presented by Wirth et al at the European Society for Medical Oncology...
ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain
Patients with ALK-positive non–small cell lung cancer (NSCLC) that was metastatic to the brain at baseline demonstrated whole-body, intracranial, and extracranial responses following treatment with ceritinib, according to findings from the phase II ASCEND-7 study presented by Chow et al at the...
ESMO 2019: ctDNA as a Marker for Disease-Free Survival With Oxaliplatin Treatment in Stage III Colon Cancer
Patients with advanced colon cancer and plasma samples containing circulating tumor DNA (ctDNA) were less likely to achieve 2-year disease-free survival with oxaliplatin-based adjuvant treatment than patients with ctDNA-negative samples, according to findings presented at the European Society for...
ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer
Two studies presented at the European Society for Medical Oncology (ESMO) 2019 Congress showed the efficacy of poly ADP ribose polymerase (PARP) inhibitors in patients with newly diagnosed ovarian cancer. In the PRIMA/ENGOT-OV26/GOG-3012 study, presented by González Martín et al (Abstract LBA1;...
ESMO 2019: Tailored Treatment vs Empiric Chemotherapy for Cancer of an Unknown Primary
Treatment tailored by comprehensive molecular gene-expression analysis of tumors from patients with carcinomas of an unknown primary site did not improve progression-free survival vs empiric chemotherapy consisting of cisplatin/gemcitabine. Fizazi et al presented these findings at the European...
ESMO 2019: 5-Year Survival and Response With Nivolumab/Ipilimumab in Advanced Melanoma
An update of results of the phase III CheckMate 067 trial at 5 years presented by Larkin et al at the European Society for Medical Oncology (ESMO) 2019 Congress showed that both nivolumab in combination with ipilimumab and nivolumab alone provided significant improvements in overall survival,...
ESMO 2019: First-Line Immunotherapy Shows Clinical Benefit in Advanced Hepatocellular Carcinoma
New data have shown a trend toward clinically meaningful improvements in survival and response rates and a favorable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC). The data, reported by Yau et al at the European...
ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds
Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA49_PR). The study answers a long-standing question about whether...
FDA Announces Voluntary Recall of Certain Ranitidine Capsules
This week, the U.S. Food and Drug Administration (FDA) alerted health-care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc, used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine...
Ned Sharpless, MD, Testifies Before House Subcommittee on FDA Investigation of Vaping Illnesses and Regulation of E-Cigarettes
Earlier this week, Acting Commissioner of the U.S. Food and Drug Administration (FDA) Ned Sharpless, MD, testified before the U.S. House Energy and Commerce Subcommittee on the FDA’s planned regulation of electronic nicotine delivery systems and investigation of vaping illnesses. His remarks are...
Cancer Prevention and Research Institute of Texas Awards $136 Million in New Grants
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded 71 new grants, totaling close to $136 million, to advance cancer research. This total includes 58 academic research grant awards, 10 prevention awards, and 3 product development research awards. CPRIT has now brought 181 ...
International Collaboration Announces Additional NCCN Harmonized Guidelines for Sub-Saharan Africa
To improve cancer outcomes in Sub-Saharan Africa, a collaborative project from the National Comprehensive Cancer Network® (NCCN®), the African Cancer Coalition (ACC), the American Cancer Society, and others recently entered a new phase in Addis Ababa, Ethiopia. Oncologists from 11 African...
